Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a robust financial performance for the first quarter of 2024. The company's sales surged by 22% in Danish kroner and 24% at constant exchange rates (CER) to DKK 65.3 billion. The operating profit followed suit, increasing by 27% in Danish kroner and 30% at CER to DKK 31.8 billion. North America Operations, particularly the US market, contributed significantly to this growth with a 34% increase in sales. The company's Diabetes and Obesity care segment saw a 25% rise in sales, driven by GLP-1 diabetes sales and Obesity care. However, rare disease sales experienced a slight decline. Notably, Novo Nordisk completed the FLOW kidney outcomes trial and received US approval for Wegovy for cardiovascular risk reduction...Show More

Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a robust financial performance for the first quarter of 2024. The company's sales surged by 22% in Danish kroner and 24% at constant exchange rates (CER) to DKK 65.3 billion. The operating profit followed suit, increasing by 27% in Danish kroner and 30% at CER to DKK 31.8 billion. North America Operations, particularly the US market, contributed significantly to this growth with a 34% increase in sales. The company's Diabetes and Obesity care segment saw a 25% rise in sales, driven by GLP-1 diabetes sales and Obesity care. However, rare disease sales experienced a slight decline. Notably, Novo Nordisk completed the FLOW kidney outcomes trial and received US approval for Wegovy for cardiovascular risk reduction. Additionally, the company announced an agreement to acquire three fill-finish sites from Novo Holdings A/S. Looking ahead, Novo Nordisk has raised its 2024 outlook, expecting sales growth of 19-27% and operating profit growth of 22-30% at CER. The company's financial report was prepared in accordance with IAS 34 'Interim Financial Reporting' and Danish disclosure requirements.